Draftfcb Healthcare merges 2 of its branches

Share this article:
Area 23: Absorbing smaller unit
Area 23: Absorbing smaller unit

Project X-Ray and Area 23, two Manhattan agencies that spun out of Interpublic Group's Draftfcb Healthcare unit last year, are merging.

Project X-Ray, which handled several Pfizer accounts, will be absorbed by Area 23, a full-service healthcare communications business located on 23rd street. Its larger counterpart, Draftfcb Healthcare, is on 33rd.

The 70-person, mid-sized agency was conceived to service clients including Roche's Phase III rheumatoid arthritis compound Actemra, US and global, and its anemia biologic Mircera, global. It will now handle Project X-Ray's Pfizer business, including antibiotic Zmax and migraine drug Relpax.

Other Area 23 accounts include the Boehringer Ingelheim Mycardis franchise (hypertension), a new assignment, and GlaxoSmithKline's Lamictal (bipolar/epilepsy), which has been handled by Draftfcb Healthcare since 2003.

Matt Lane, who had been EVP/group management director for Project X-Ray, has joined Area 23, according to an announcement yesterday heralding the agency's “official” launch.

Area 23 provides a blend of professional, patient and managed care services for the accounts.

Share this article:

Email Newsletters

More in News

Gilead reaps huge HCV sales, payer fury

Gilead reaps huge HCV sales, payer fury

Sovaldi's debut has been marked by plenty of criticism from payers and lawmakers, but the hep. C drug's launch, now confirmed to be the fastest of all time, has also ...

Bayer drug gets orphan label

Bayer drug gets orphan label

The FDA designation is for an experimental, inhaled form of ciprofloxacin intended to treat a rare lung condition.

Lilly's cancer drug ramu granted gastric indication

Lilly's cancer drug ramu granted gastric indication

Ramucirumab received FDA approval today in advanced gastric cancer, a nod that could translate into $600 million in peak sales.